Zacks Investment Research upgraded shares of Black Diamond Therapeutics (NASDAQ:REYN) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $35.00 target price on the stock.
According to Zacks, “Reynolds Consumer Products Inc. is a consumer branded and private label products company. It produces and sells branded and store-brand products which includes cooking products, waste & storage products and tableware. The company’s flagship products include Reynolds Wrap(R) aluminum foil, Hefty(R) bags, and Hefty(R) party cups. Reynolds Consumer Products Inc. is based in Lake Forest, Illinois. “
Several other research analysts have also issued reports on REYN. ValuEngine lowered Black Diamond Therapeutics from a hold rating to a sell rating in a research report on Friday, August 7th. BidaskClub upgraded Black Diamond Therapeutics from a sell rating to a hold rating in a research report on Friday, September 25th. Finally, JPMorgan Chase & Co. raised their price target on Black Diamond Therapeutics from $37.00 to $38.00 and gave the stock an overweight rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. Black Diamond Therapeutics presently has an average rating of Buy and an average target price of $36.40.
Shares of REYN opened at $31.24 on Wednesday. The firm has a market capitalization of $6.55 billion and a price-to-earnings ratio of 21.54. The company has a debt-to-equity ratio of 1.63, a quick ratio of 1.82 and a current ratio of 2.81. The business’s fifty day moving average price is $31.76 and its two-hundred day moving average price is $32.57. Black Diamond Therapeutics has a 52 week low of $21.61 and a 52 week high of $36.00.
Black Diamond Therapeutics (NASDAQ:REYN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.03. The firm had revenue of $798.00 million during the quarter, compared to the consensus estimate of $853.11 million. The company’s revenue for the quarter was up 6.0% on a year-over-year basis. As a group, research analysts forecast that Black Diamond Therapeutics will post 1.94 EPS for the current year.
In other Black Diamond Therapeutics news, Director Richard A. Noll acquired 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were acquired at an average price of $33.41 per share, with a total value of $501,150.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
A number of institutional investors have recently modified their holdings of REYN. State Street Corp acquired a new stake in Black Diamond Therapeutics during the 1st quarter worth $14,374,000. Victory Capital Management Inc. acquired a new stake in Black Diamond Therapeutics during the 1st quarter worth $235,000. Parametric Portfolio Associates LLC acquired a new stake in Black Diamond Therapeutics during the 1st quarter worth $240,000. Alliancebernstein L.P. acquired a new stake in shares of Black Diamond Therapeutics in the 1st quarter valued at about $14,876,000. Finally, Deutsche Bank AG acquired a new stake in shares of Black Diamond Therapeutics in the 1st quarter valued at about $67,000. 26.16% of the stock is currently owned by institutional investors and hedge funds.
About Black Diamond Therapeutics
Reynolds Consumer Products Inc, a consumer products company, produces and sells products across cooking, waste and storage, and tableware. It operates through four segments: Reynolds Cooking & Baking, Hefty Waste & Storage, Hefty Tableware, and Presto Products. The Reynolds Cooking & Baking segment produce foil, parchment paper, and disposable aluminum pans, as well as cooker liners.
Further Reading: How is the S&P 500 index different from the DJIA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.